Healthcare Business

Achillion Pharmaceuticals Gears Up for Secondary Offering

Shares of Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) saw a handy gain on Thursday after the company announced a secondary offering. While the offering is set to close on November 20, ...
Read Full Story »

Acorda Therapeutics Gets Crushed After Halting Parkinson’s Trial

Acorda Therapeutics Inc. (NASDAQ: ACOR) saw its shares drop sharply following an update on its Parkinson’s trial. The company paused new enrollment in the long-term safety studies, pending further discussion ...
Read Full Story »

Loxo Loses Out Despite Signing Big Cancer Deal

Loxo Oncology Inc. (NASDAQ: LOXO) saw its shares dip on Tuesday after the company announced that it will be partnering with Bayer to develop and commercialize larotrectinib and LOXO-195. Even ...
Read Full Story »

Why Argus Is Taking a Step Back on Gilead Sciences

Gilead Sciences Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded the stock. Many investors have hoped that the shares will ...
Read Full Story »

Short Sellers Back Way Off Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

3 Companies Spearheading the Antibiotics Space in 2018

This may turn out to be a pivotal year in antibiotic development, after decades of dramatic decline in the space. While 1980 to 1984 saw 18 new antibiotic approvals, the ...
Read Full Story »

Biosimilars Have Massive Sales Potential: 5 Top Drug Stocks to Buy Now

During the presidential campaign of 2015–2016, one of the areas that got some of the largest scrutiny was drug pricing, and with good reason. Spending on pharmaceuticals when the population ...
Read Full Story »

Sage Therapeutics Wins Big in Depression Trial

Sage Therapeutics Inc. (NASDAQ: SAGE) shares absolutely exploded on Thursday after the firm announced top-line results from its late-stage trial in severe postpartum depression (PPD). Ultimately the Phase 3 clinical ...
Read Full Story »

Why Otonomy Shares Are Skyrocketing

Otonomy Inc. (NASDAQ: OTIC) reported its most recent quarterly results after the markets closed on Wednesday and gave an update on its late-stage trial in patients with Ménière’s disease. Although ...
Read Full Story »

Voyager Therapeutics Gears Up for Secondary Offering

Voyager Therapeutics Inc. (NASDAQ: VYGR) has seen a decent year for its shares and now seems like a good time to cash in. Although the past month has not been ...
Read Full Story »

Keryx Biopharmaceuticals FDA Win Outweighed by Q3 Loss

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) shares took a big step back on Tuesday after the company announced its third-quarter results and an update from the U.S. Food and Drug Administration ...
Read Full Story »

Valeant Earnings Soar on Tax Benefit

Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported third-quarter 2017 results before markets opened Tuesday. The company reported quarterly diluted earnings per share (EPS) of $3.69 and revenues of $2.22 billion. ...
Read Full Story »

Why Solid CVS Health Earnings Are Not Enough

When CVS Health Corp. (NYSE: CVS) reported its third-quarter financial results early Monday, the company said that it had $1.50 in earnings per share (EPS) on $46.2 billion in revenue. ...
Read Full Story »

Why Mylan Shares Were Bouncing Around After Q3 Earnings

Mylan N.V. (NASDAQ: MYL) reported third-quarter 2017 earnings before markets opened Monday. The pharmaceuticals company posted adjusted earnings per share (EPS) of $1.10 on revenues of $2.99 billion. In the ...
Read Full Story »

Sarepta Takes Another Big Step Forward With DMD Treatment

Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw its shares hit a new multiyear high on Friday after the firm announced that it received a key approval from the U.S. Food and ...
Read Full Story »